Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Cannabidiol · 1 trial · 2 indications
The SAFTEE is a multi-symptom checklist that has been used successfully in the investigators previous studies to assess and monitor any adverse events and possible side effects of study medications. It includes information regarding the severity of any presenting symptoms (0= none, 1= mild, 2= moderate, and 3= severe), as well as the course of action taken by the study staff in response. The SAFTEE is administered before the administration of CBD at baseline, (timepoint -30 minutes) and 4 hours after the administration of CBD (timepoint +240 minutes) during each test session. Data will be presented as the number of participants that reported symptoms on the SAFTEE.
The DEQ will be administered to assess the abuse potential of CBD. The DEQ is a 10-item questionnaire used to assess the subjective effects of psychoactive drugs. Each item is a visual analogue scale (VAS) ranging from 0-100. The questionnaire is used to measure whether a subject feels the drug "feels high", likes or dislikes the effects, and whether they want more of the drug. The primary DEQ outcome will be the Stimulatory Effects subscale, obtained by averaging participants responses to the items: "Feel High"; "Feel Stimulated"; and "Feel the Drug Strength".
The HVLT will be used to assess the cognitive effects of CBD. The primary outcomes will be immediate and delayed recall, which index verbal memory. The HVLT consists of a 12-item word list, composed of four words from each of the three semantic categories. The participant is instructed to listen carefully as the examiner reads the word list and attempt to memorize the words. The participants' free recall of the list is recorded. The same procedure is repeated for two more trials (immediate recall). After approximately 15 minutes the participant will be asked to recall as many words from the list as they can without the list being re-read to them (delayed recall).
The cognitive/psychomotor effects of CBD will be assessed using the Continuous Performance Test (CPT). CPT is a computerized neuropsychological assessment that measures participants sustained and selective attention. For the CPT, the primary outcome will be the throughput score, which indexes attention/working memory accuracy (i.e. percent of correct responses) and speed (i.e. reaction time).
| Arm | Type | Description |
|---|---|---|
| CBD 400 mg | ACTIVE_COMPARATOR | CBD 400 mg |
| CBD 800 mg | ACTIVE_COMPARATOR | CBD 800mg |
| CBD 1200 mg | ACTIVE_COMPARATOR | CBD 1200 mg |
| Beta carotene oral solution | PLACEBO_COMPARATOR | Beta carotene oral solution without CBD |
| Name | Type | Description |
|---|---|---|
| 400 mg Cannabidiol | DRUG | Participants will receive 400 mg CBD |
| 800 mg Cannabidiol | DRUG | Participants will receive 800 mg CBD |
| 1200 mg Cannabidiol | DRUG | Participants will receive 1200 mg CBD |
| Beta carotene oral solution without CBD | DRUG | Participants will receive beta carotene oral solution without CBD (placebo) |
Inclusion Criteria: * Males and females, Veterans and non-Veterans, aged between 18 and 70 years old. * Diagnosed with OUD and currently enrolled in methadone or buprenorphine maintenance treatment. * Having chronic pain, uniformly operationalized as grade II (high-intensity) non-cancer pain for ≥ ...
Cannabidiol is an investigational small molecule being developed for chronic pain. It is currently in Phase 1 clinical development. The drug is being studied in patients with chronic pain and opioid use disorder, with a focus on pain management in this population.
Cannabidiol's molecular target has not been specified in the available information. It is a small molecule being studied for its effects on chronic pain, but the specific biological target or mechanism of action has not been disclosed.
Cannabidiol is being developed by National Healthcare Corp. (ticker: NHC). The company is conducting clinical trials to evaluate the drug for chronic pain. The drug is currently in Phase 1 development.
Cannabidiol is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing trial is an early Phase 1 study that is currently recruiting participants.
Cannabidiol is being studied in a Phase 1 clinical trial with the identifier NCT04587791. This trial is titled 'Cannabidiol in Opioid Use Disorder and Chronic Pain' and is recruiting 34 participants in the United States. The study is randomized, double-blind, and placebo-controlled.
Yes, Cannabidiol is also known as 400 mg Cannabidiol. This alternative name refers to the specific dosage form being studied in clinical trials. Both names refer to the same investigational drug being developed by National Healthcare Corp.